Huang Yu-Ting, Ravi Kumar Aravind S, Bhuta Sandeep
aDepartment of Nuclear Medicine and Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston bDepartment of Medical Imaging, Gold Coast University Hospital cSchool of Medicine, Griffith University, Southport dSchool of Medicine, University of Queensland, St Lucia, Queensland, Australia.
Nucl Med Commun. 2015 Jan;36(1):16-20. doi: 10.1097/MNM.0000000000000208.
There is evidence that the status of human papilloma virus subtype 16 (HPV-p16) alters the prognosis of patients with oropharyngeal squamous cell cancer (OSCC). We sought to establish whether there is a relationship between HPV-p16 status and 18F-FDG uptake in the prognosis of OSCC.
Patients with newly diagnosed OSCC at our institution between June 2011 and June 2012 were retrospectively evaluated. All patients underwent a baseline 18F-FDG PET/computed tomographic scan and HPV-p16 testing. Tumour maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) and total glycolytic activity (TGA) [defined as metabolic tumour volume (MTV) multiplied by SUVmean] were measured. All PET/computed tomographic scans were reviewed on a Siemens Syngo.via (version VA11B_HF03) workstation. A designated operator defined the region of the primary tumour with the MTV segmented by 40% of the SUVmax fixed threshold method.
Seventy-nine patients aged 27-84 years met the criteria for inclusion in the study. The types of primary tumour were tonsillar squamous cell carcinoma in 48% and base of tongue squamous cell carcinoma in 29%. The mean SUVmax was 17.5 and 17.7 in HPV-p16-positive and HPV-p16-negative groups, respectively (P=0.90). The mean MTV was 8.36 and 7.07 ml in HPV-p16-positive and HPV-p16-negative patients, respectively (P=0.42). The mean TGA values were 96.3 and 82.5 g among the HPV-p16-positive and HPV-p16-negative patients (P=0.54). There was no significant difference between HPV-p16 status and tumour grading for any of the imaging markers.
There were no statistically significant differences between HPV-p16-positive and HPV-p16-negative OSCC for any of the metabolic imaging markers (SUVmax, SUVmean, MTV and TGA) measured in this study.
有证据表明人乳头瘤病毒16型（HPV-p16）状态会改变口咽鳞状细胞癌（OSCC）患者的预后。我们试图确定在OSCC预后中HPV-p16状态与18F-FDG摄取之间是否存在关联。
对2011年6月至2012年6月期间在我院新诊断为OSCC的患者进行回顾性评估。所有患者均接受了基线18F-FDG PET/计算机断层扫描及HPV-p16检测。测量肿瘤最大标准化摄取值（SUVmax）、平均标准化摄取值（SUVmean）和总糖酵解活性（TGA）[定义为代谢肿瘤体积（MTV）乘以SUVmean]。所有PET/计算机断层扫描均在西门子Syngo.via（版本VA11B_HF03）工作站上进行回顾。一名指定操作人员通过SUVmax固定阈值法的40%分割MTV来定义原发性肿瘤区域。
79例年龄在27 - 84岁的患者符合纳入本研究的标准。原发性肿瘤类型中，扁桃体鳞状细胞癌占48%，舌根鳞状细胞癌占29%。HPV-p16阳性组和HPV-p16阴性组的平均SUVmax分别为17.5和17.7（P = 0.90）。HPV-p16阳性和阴性患者的平均MTV分别为8.36和7.07 ml（P = 0.42）。HPV-p16阳性和阴性患者的平均TGA值分别为96.3和82.5 g（P = 0.54）。对于任何影像学标志物，HPV-p16状态与肿瘤分级之间均无显著差异。
在本研究中测量的任何代谢影像学标志物（SUVmax、SUVmean、MTV和TGA）方面，HPV-p16阳性和阴性的OSCC之间均无统计学显著差异。
